Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.
We identified three cross-neutralizing plasma samples with high-titer anti-membrane proximal external region (MPER) peptide binding antibodies from among 156 chronically human immunodeficiency virus type 1-infected individuals. In order to establish if these antibodies were directly responsible for the observed neutralization breadth, we used MPER-coated magnetic beads to deplete plasmas of these specific antibodies. Depletion of anti-MPER antibodies from BB34, CAP206, and SAC21 resulted in 77%, 68%, and 46% decreases, respectively, in the number of viruses neutralized. Antibodies eluted from the beads showed neutralization profiles similar to those of the original plasmas, with potencies comparable to those of the known anti-MPER monoclonal antibodies (MAbs), 4E10, 2F5, and Z13e1. The anti-MPER neutralizing antibodies in BB34 were present in the immunoglobulin G3 subclass-enriched fraction. Alanine scanning of the MPER showed that the antibodies from these three plasmas had specificities distinct from those of the known MAbs, requiring one to three crucial residues at positions 670, 673, and 674. These data demonstrate the existence of MPER-specific cross-neutralizing antibodies in plasma, although the ability to elicit such potent antiviral antibodies during natural infection appears to be rare. Nevertheless, the identification of three novel antibody specificities within the MPER supports its further study as a promising target for vaccine design.
Gray
Elin S
ES
AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa.
Madiga
Maphuti C
MC
Moore
Penny L
PL
Mlisana
Koleka
K
Abdool Karim
Salim S
SS
Binley
James M
JM
Shaw
George M
GM
Mascola
John R
JR
Morris
Lynn
L
D000327:Adsorption; D000595:Amino Acid Sequence; D000906:Antibodies / Q000097:blood / Q000276:immunology; D018604:Epitope Mapping; D015700:HIV Envelope Protein gp41 / Q000737:chemistry* / Q000235:genetics / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D018189:Immunomagnetic Separation; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D017434:Protein Structure, Tertiary
D000906:Antibodies; D015700:HIV Envelope Protein gp41
J Virol. 2009 Sep;83(17):8451-62
19515770
J Virol. 2008 Mar;82(5):2367-75
18094155
J Virol. 2005 Jan;79(2):1252-61
15613352
Science. 2005 Jun 24;308(5730):1906-8
15860590
Immunity. 2008 Jan;28(1):52-63
18191596
Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9057-62
19458040
J Virol. 2009 Jan;83(2):757-69
18987148
J Virol. 2009 Jan;83(2):1045-59
19004942
J Virol. 1999 Mar;73(3):2469-80
9971832
J Infect Dis. 1997 Oct;176(4):924-32
9333150
J Virol. 2007 Jun;81(12):6187-96
17409164
J Virol. 2009 Sep;83(17):8925-37
19553335
Curr Opin HIV AIDS. 2009 Sep;4(5):364-72
20048699
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9
12644702
J Virol. 2009 Apr;83(8):3617-25
19193787
J Virol. 2009 Aug;83(15):7397-410
19458010
Curr Pharm Des. 2007;13(2):213-27
17269929
J Intern Med. 2007 Jul;262(1):26-43
17598813
J Virol. 2001 Nov;75(22):10892-905
11602729
J Virol. 2001 Jul;75(14):6558-65
11413323
J Virol. 2004 Dec;78(23):13232-52
15542675
AIDS. 2005 Nov 4;19(16):1725-37
16227780
Biotechnol Bioeng. 2000 Jan 5;67(1):97-103
10581440
AIDS Res Hum Retroviruses. 2004 Jul;20(7):755-62
15307922
J Virol. 2007 Apr;81(8):4033-43
17287272
J Virol. 2004 Oct;78(19):10724-37
15367639
J Virol. 1997 May;71(5):3734-41
9094648
PLoS One. 2008 Apr 16;3(4):e1954
18414658
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3739-44
18322015
J Virol. 2006 Mar;80(6):3030-41
16501112
Nat Med. 2009 Aug;15(8):866-70
19525964
AIDS. 2006 Oct 3;20(15):1923-30
16988513
J Virol. 2003 May;77(10):5678-84
12719560
AIDS. 2002 Feb 15;16(3):501-3
11834970
J Virol. 2009 Jan;83(1):188-99
18922865
J Virol. 2008 Dec;82(23):11651-68
18815292
PLoS Med. 2006 Jul;3(7):e255
16834457
Curr Protoc Immunol. 2005 Jan;Chapter 12:12.11.1-12.11.17
18432938